Pharmaceutical Technology

APRIL 19, 2024

Researchers at the National Cancer Institute, a unit of the National Institutes of Health (NIH) in the US, have developed an AI tool that can predict drug responses in cancer treatment.

Development 147

Development Drugs Research 147

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 22 drugs in development for Inherited Mitochondrial Disorders by 19 companies/universities/institutes. The top development phase for Inherited Mitochondrial Disorders is preclinical, with 13 drugs in that stage.

Development 130

Development Drugs 130

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 46 drugs in development for Lewy Body Dementia by 36 companies/universities/institutes. The top development phase for Lewy Body Dementia is preclinical, with 21 drugs in that stage.

Development 130

Development Drugs 130

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 150 drugs in development for Gastroesophageal (GE) Junction Carcinomas by 115 companies/universities/institutes. The top development phase for Gastroesophageal (GE) Junction Carcinomas is phase ii, with 72 drugs in that stage.

Development 130

Development Drugs 130

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 5 drugs in development for Choriocarcinoma (Gestational Trophoblastic Neoplasia) by four companies/universities/institutes. The top development phase for Choriocarcinoma (Gestational Trophoblastic Neoplasia) is phase i, with four drugs in that stage.

Development 130

Development Drugs 130

Bio Pharma Dive

NOVEMBER 13, 2023

How can these increase the probability of success or efficiency in a pre-clinical and clinical drug development program? Regulatory agencies have set the framework and use cases for RWE.

Development 269

Development Drugs 269

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Remote-controlled robotic labs.

Development 311

Development Drugs Pharma Companies Life Science 311

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 8 drugs in development for Choroideremia by eight companies/universities/institutes. The top development phase for Choroideremia is preclinical, with four drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 23 drugs in development for Monkeypox by 19 companies/universities/institutes. The top development phase for Monkeypox is preclinical, with 11 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 59 drugs in development for Conjunctivitis by 51 companies/universities/institutes. The top development phase for Conjunctivitis is preclinical, with 20 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 198 drugs in development for Retinopathy by 163 companies/universities/institutes. The top development phase for Retinopathy is preclinical, with 131 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 5 drugs in development for Blepharospasm by four companies/universities/institutes. The top development phase for Blepharospasm is phase ii, with two drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

APRIL 16, 2024

in a Series A funding round led by Hargreave Hale AIM VCT to accelerate drug development. Qureight has secured $8.5m

Development 130

Development Drugs 130

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 58 drugs in development for Beta Thalassaemia by 56 companies/universities/institutes. The top development phase for Beta Thalassaemia is preclinical, with 20 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 3 drugs in development for Palmoplantar Pustulosis by three companies/universities/institutes. The top development phase for Palmoplantar Pustulosis is preclinical, with one drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 76 drugs in development for Retinal Degeneration by 63 companies/universities/institutes. The top development phase for Retinal Degeneration is preclinical, with 40 drugs in that stage.

Development 100

Development Drugs 100

Bio Pharma Dive

MAY 1, 2023

Founded by Sam Waksal, Graviton Biosciences is developing drugs that block an enzyme called ROCK2, which drew the interest of neurology-focused Ovid.

Development 325

Development Drugs 325

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 5 drugs in development for Meibomian Blepharitis by six companies/universities/institutes. The top development phase for Meibomian Blepharitis is phase ii, with three drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

DECEMBER 4, 2023

GlobalData tracks 4 drugs in development for Cat Allergy by four companies/universities/institutes. The top development phase for Cat Allergy is preclinical, with two drugs in that stage.

Allergies 130

Allergies Development Drugs 130

Pharmaceutical Technology

NOVEMBER 30, 2023

GlobalData tracks 13 drugs in development for Pemphigus Vulgaris by 12 companies/universities/institutes. The top development phase for Pemphigus Vulgaris is preclinical, with seven drugs in that stage.

Development 130

Development Drugs 130

Pharmaceutical Technology

NOVEMBER 30, 2023

GlobalData tracks 11 drugs in development for Bullous Pemphigoid by 12 companies/universities/institutes. The top development phase for Bullous Pemphigoid is phase ii, with six drugs in that stage.

Development 130

Development Drugs 130

Pharmaceutical Technology

JUNE 1, 2023

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. It will focus on studying and developing new lipid nanoparticle (LNP) formulations for the delivery of RNA medicine.

Drug Delivery 242

Drug Delivery RNA Development Drugs 242

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 22 drugs in development for Inherited Mitochondrial Disorders by 19 companies/universities/institutes. The top development phase for Inherited Mitochondrial Disorders is preclinical, with 13 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 46 drugs in development for Lewy Body Dementia by 36 companies/universities/institutes. The top development phase for Lewy Body Dementia is preclinical, with 21 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China.

Development 246

Development Drugs Clinical Development Licensing 246

pharmaphorum

FEBRUARY 14, 2024

Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.

Development 128

Development FDA Approval Drugs Compliance 128

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 8 drugs in development for Chemotherapy-Induced Diarrhea (CID) by seven companies/universities/institutes. The top development phase for Chemotherapy-Induced Diarrhea (CID) is preclinical, with two drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 71 drugs in development for Chronic Myelomonocytic Leukemia (CMML) by 58 companies/universities/institutes. The top development phase for Chronic Myelomonocytic Leukemia (CMML) is phase i, with 29 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 150 drugs in development for Gastroesophageal (GE) Junction Carcinomas by 115 companies/universities/institutes. The top development phase for Gastroesophageal (GE) Junction Carcinomas is phase ii, with 72 drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

MARCH 20, 2024

GlobalData tracks 5 drugs in development for Choriocarcinoma (Gestational Trophoblastic Neoplasia) by four companies/universities/institutes. The top development phase for Choriocarcinoma (Gestational Trophoblastic Neoplasia) is phase i, with four drugs in that stage.

Development 100

Development Drugs 100

Pharmaceutical Technology

NOVEMBER 30, 2023

GlobalData tracks 15 drugs in development for Herpes Labialis (Oral Herpes) by 11 companies/universities/institutes. The top development phase for Herpes Labialis (Oral Herpes) is preclinical, with six drugs in that stage.

Development 130

Development Drugs 130

AuroBlog - Aurous Healthcare Clinical Trials blog

FEBRUARY 15, 2024

a global leader in analytical and clinical laboratory technologies, announced that it has received two prestigious awards from SelectScience: Best New Drug Discovery & Development Product of 2023 and Drug Discovery & Development Webinar of the Year. Agilent Technologies Inc., The […]

Production 149

Production Development Scientist Drugs 149

Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The US Food and Drug Administration has granted fast-track designation to SNIPR001, which is currently in clinical development.

Development 246

Development Bacteria Research Gene Editing 246

Pharmaceutical Technology

NOVEMBER 30, 2023

The Herpes Labialis (Oral Herpes) drugs in development market research report provides comprehensive information on the therapeutics under development for…

Development 130

Development Drugs Marketing Research 130

Bio Pharma Dive

MARCH 25, 2024

Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

Drugs 161

Drugs Development 161